Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region

Cancer Research

Volumn 63, Issue 8, 2003, Pages 1920-1926

  Maula, Sanna Mari ^a,d   Luukkaa, Marjaana ^b   Grénman, Reidar ^b   Jackson, David ^c   Jalkanen, Sirpa ^a   Ristamäki, Raija ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; HERMES ANTIGEN; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1;

ARTICLE; BLOOD VESSEL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DENSITY; FEMALE; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; AMINE OXIDASE (COPPER-CONTAINING); ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; COMBINED MODALITY THERAPY; FEMALE; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0344406080     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ferlay, J., Bray, F., Pisani, P., and Parkin, D. M. Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase, 2000.
2. Maier, H., Dietz, A., Gewelke, U., Heller, W. D., and Weidauer, H. Tobacco and alcohol and the risk of head and neck cancer. Clin. Investig., 70: 320-327, 1992.
3. Quon, H., Liu, F. F., and Cummings, B. J. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck, 23: 147-159, 2001.
4. Lingen, M. W., Emami, B., and Clark, J. 1. New therapeutic strategies for the treatment and prevention of head and neck cancer. Expert Opin. Investig. Drugs, 9: 2855-2872, 2000.
5. Poole, M. E., Sailer, S. L., Rosenman, J. G., Tepper, J. E., Weissler, M. C., Shockley, W. W., Yarbrough, W. G., Pillsbury, H. C. 3rd, Schell, M. J., and Bernard, S. A. Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation. Arch. Otolaryngol. Head Neck Surg., 127: 1446-14500, 2001.
6. Belbin, T. J., Singh, B., Barber, I., Socci, N., Wenig, B., Smith, R., Prystowsky, M. B., and Childs, G. Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res., 62: 1184-1190, 2002.
7. Lakhani, S. R., and Ashworth, A. Microarray and histopathological analysis of tumours: the future and the past?. Nat. Rev. Cancer, 1: 151-157, 2001.
8. Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin, M. E., Kim, J. Y., Goumnerova, L. C., Black, P. M., Lau, C., Allen, J. C., Zagzag, D., Olson, J. M., Curran, T., Wetmore, C., Biegel, J. A., Poggio, T., Mukherjee, S., Rifkin, R., Califano, A., Stolovitzky, G., Louis, D. N., Mesirov, J. P., Lander, E. S., and Golub, T. R. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (Lond.), 415: 436-442, 2002.
9. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature (Lond.), 415: 530-536, 2002.
10. Dachs, G. U., and Tozer, G. M. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur. J. Cancer, 36: 1649-1660, 2000.
11. Hiraoka, N., Allen, E., Apel, I. J., Gyetko, M. R., and Weiss, S. J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell, 95: 365-377, 1998.
12. Westermarck, J., and Kähäri, V. M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13: 781-792, 1999.
13. Johansson, N., Ahonen, M., and Kähäri, V. M. Matrix metalloprotenaises in tumor invasion. Cell. Mol. Life Sci., 57: 5-15, 2000.
14. Dictor, M., Ehinger, M., Mertens, F., Akervall, J., and Wennerberg, J. Abnormal cell cycle regulation in malignancy. Am. J. Clin. Pathol., 112: S40-52, 1999.
15. Duffy, M. J. Clinical uses of tumor markers: a critical review. Crit. Rev. Clin. Lab. Sci., 38: 225-262, 2001.
16. Toi, M., Matsumoto, T., and Bando, H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol., 2: 667-673, 2001.
17. Herrera-Gayol, A., and Jothy, S. Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp. Mol. Pathol., 66: 149-156, 1999.
18. Drillenburg, P., and Pals, S. T. Cell adhesion receptors in lymphoma dissemination. Blood, 95: 1900-1910, 2000.
19. Naor, D., Sionov, R. V., and Ish-Shalom, D. CD44: structure, function, and association with the malignant process. Adv. Cancer Res., 71: 241-319, 1997.
20. Banerji, S., Ni, J., Wang, S. X., Clasper, S., Su, J., Tammi, R., Jones, M., and Jackson, D. G. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol., 144: 789-801, 1999.
21. Jain, R. K., and Fenton, B. T. Intratumoral lymphatic vessels: a case of mistaken identity of malfunction?. J. Natl. Cancer Inst. (Bethesda), 94: 417-421, 2002.
22. Kriehuber, E., Breiteneder-Geleff, S., Groeger, M., Soleiman, A., Schoppmann, S. F., Stingl, G., Kerjaschki, D., and Maurer, D. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J. Exp. Med., 194: 797-808, 2001.
23. Jackson, D. G., Prevo, R., Clasper, S., and Banerji, S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol., 22: 317-321, 2001.
24. Salmi, M., and Jalkanen, S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science (Wash. DC), 257: 1407-1409, 1992.
25. Salminen, T. A., Smith, D. J., Jalkanen, S., and Johnson, M. S. Structural model of the catalytic domain of an enzyme with cell adhesion activity: human vascular adhesion protein-1 (HVAP-1) D4 domain is an amine oxidase. Protein Eng., 11: 1195-1204, 1998.
26. Yoong, K. F., McNab, G., Hubscher, S. G., and Adams, D. H. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor- infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J. Immunol., 160: 3978-3988, 1998.
27. Irjala, H., Salmi, M., Alanen, K., Grenman, R., and Jalkanen, S. Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium. J. Immunol., 166: 6937-6943, 2001.
28. Jalkanen, S., Bargatze, R. F., de los Toyos, J., and Butcher, E. C. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J. Cell Biol., 105: 983-990, 1987.
29. Ristamäki, R., Joensuu, H., Lappalainen, K., Teerenhovi, L., and Jalkanen, S. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma. Blood, 90: 4039-4045, 1997.
30. Maula, S., Huuhtanen, R. L., Blomqvist, C. P., Wiklund, T. A., Laurila, P., and Ristamaki, R. The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas. Br. J. Cancer, 84: 244-252, 2001.
31. Bono, P., Salmi, M., Smith, D. J., and Jalkanen, S. Cloning and characterization of mouse vascular adhesion protein-1 reveals a novel molecule with enzymatic activity. J. Immunol., 160: 5563-5571, 1998.
32. Beasley, N. J., Prevo, R., Banerji, S., Leek, R. D., Moore, J., van Trappen, P., Cox, G., Harris, A. L., and Jackson, D. G. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res., 62: 1315-1320, 2002.
33. Padera, T. P., Kadambi, A., di Tomaso, E., Carreira, C. M., Brown, E. B., Boucher, Y., Choi, N. C., Mathisen, D., Wain, J., Mark, E. J., Munn, L. L., and Jain, R. K. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (Wash. DC), 296: 1883-1886, 2002.
34. Schoppmann, S. F., Birner, P., Stockl, J., Kalt, R., Ullrich, R., Caucig, C., Kriehuber, E., Nagy, K., Alitalo, K., and Kerjaschki, D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol., 161: 947-956, 2002.
35. Yasuda, M., Tanaka, Y., Fujii, K., and Yasumoto, K. CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. Int. Immunol., 13: 1309-1319, 2001.
36. Soukka, T., Salmi, M., Joensuu, H., Häkkinen, L., Sointu, P., Koulu, L., Kalimo, K., Klemi, P., Grenman, R., and Jalkanen, S. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res., 57: 2281-2289, 1997.
37. Yu, Q., and Stamenkovic, I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev., 13: 35-48, 1999.